EnSilica PLC has followed a step change in its financial performance with a fresh customer win. On 29 October 2026 the semiconductor specialist announced a US$2.4 million contract to develop and Supply an application-specific integrated circuit for a US healthcare technology company, and confirmed it had completed the tape-out of a next-generation chip for a UK life sciences customer. The news came weeks after final results showing Revenue up by more than half.

What the company does

EnSilica designs and supplies application-specific integrated circuits, known as ASICs, for customers in sectors including healthcare, satellite communications and industrial markets. It describes itself as having transitioned into a semiconductor design and supply platform. Its model combines engineering fees for chip development with longer-term revenue from supplying chips once they enter Volume production. In its latest results the company said five of its ASICs were in volume production and fourteen were in design.

Latest developments

The new US$2.4 million contract covers a wireless biosensing and therapeutic controller chip, and EnSilica said the project offers potential for substantial long-term supply volumes. The completed tape-out, a key milestone in the chip development process, relates to a previously announced US$1.6 million contract, with the majority of the revenue expected in the current financial year and potential for future production supply.

Earlier announcements this year point to growing activity across its markets. In July 2026 the company reported follow-on satellite orders, and on 3 August it announced a second-phase contract win and a new project update. On 8 September 2026 it announced an EU space and communications centre of excellence. Shareholders approved all resolutions at the Annual General Meeting on 30 October 2026.

Financial and Dividend picture

In final results published on 5 October 2026, covering the year ended 31 May 2026, EnSilica reported revenue of £27.8 million, up 53%. EBITDA rose to £5.9 million, compared with roughly break-even in the prior year. The company said its lifetime supply visibility had increased by 50% to US$375 million, and that its sales pipeline had also risen by 50% to more than US$600 million.

The group strengthened its Balance Sheet through two oversubscribed Equity raises: £10 million in March 2026 and a further £14.9 million after the year end, completed in July 2026 alongside a retail offer of up to £1 million. EnSilica said the funds would accelerate pipeline conversion and expand engineering capacity. Management described the Business as positioned for continued momentum but did not publish specific numerical guidance in the summary reviewed. As a growth-focused company reinvesting in expansion, EnSilica has not been a dividend payer.

Sector and index context

EnSilica is one of a small number of UK-listed chip design companies and a constituent of the FTSE AIM All Share Index. Demand for custom silicon has been supported by growth in connected medical devices, satellite communications and industrial automation, though the semiconductor industry remains cyclical and competitive.

Key risks

ASIC programmes take years to move from design to volume production, and customer delays or cancellations can affect the timing of supply revenue. The business depends on a limited number of key customers and on third-party foundries to manufacture its chips. Lifetime supply visibility figures depend on customers' products achieving expected volumes. The recent equity raises have diluted existing shareholders, and expanding engineering headcount will increase costs.

What to watch next

Investors will watch for further contract wins and conversion of the US$600 million-plus pipeline, progress in moving the fourteen chips in design towards volume production, and a trading update or interim results for the six months to 30 November 2026, which will show whether the growth seen last year is being maintained.